These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30364161)

  • 1. C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls.
    Jacomb I; Stanton C; Vasudevan R; Powell H; O'Donnell M; Lenroot R; Bruggemann J; Balzan R; Galletly C; Liu D; Weickert CS; Weickert TW
    Front Immunol; 2018; 9():2230. PubMed ID: 30364161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions.
    North HF; Bruggemann J; Cropley V; Swaminathan V; Sundram S; Lenroot R; Pereira AM; Zalesky A; Bousman C; Pantelis C; Weickert TW; Shannon Weickert C
    Eur Arch Psychiatry Clin Neurosci; 2021 Jun; 271(4):595-607. PubMed ID: 33760971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment.
    Steiner J; Frodl T; Schiltz K; Dobrowolny H; Jacobs R; Fernandes BS; Guest PC; Meyer-Lotz G; Borucki K; Bahn S; Bogerts B; Falkai P; Bernstein HG
    Schizophr Bull; 2020 Feb; 46(2):363-373. PubMed ID: 31504969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis.
    Lizano P; Lutz O; Xu Y; Rubin LH; Paskowitz L; Lee AM; Eum S; Keedy SK; Hill SK; Reilly JL; Wu B; Tamminga CA; Clementz BA; Pearlson GD; Gershon ES; Keshavan MS; Sweeney JA; Bishop JR
    Mol Psychiatry; 2021 Jul; 26(7):3430-3443. PubMed ID: 33060818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses.
    Miller BJ; Kandhal P; Rapaport MH; Mellor A; Buckley P
    Brain Behav Immun; 2015 Mar; 45():28-35. PubMed ID: 25542737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral complement is increased in schizophrenia and inversely related to cortical thickness.
    Ji E; Boerrigter D; Cai HQ; Lloyd D; Bruggemann J; O'Donnell M; Galletly C; Lloyd A; Liu D; Lenroot R; Weickert TW; Shannon Weickert C
    Brain Behav Immun; 2022 Mar; 101():423-434. PubMed ID: 34808287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allostatic load and reduced cortical thickness in schizophrenia.
    Chiappelli J; Kochunov P; Savransky A; Fisseha F; Wisner K; Du X; Rowland LM; Hong LE
    Psychoneuroendocrinology; 2017 Mar; 77():105-111. PubMed ID: 28027496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive insight is associated with cortical thickness in first-episode psychosis.
    Buchy L; Barbato M; MacMaster FP; Bray S; Clark D; Deighton S; Addington J
    Schizophr Res; 2016 Apr; 172(1-3):16-22. PubMed ID: 26899212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis.
    Johnsen E; Fathian F; Kroken RA; Steen VM; Jørgensen HA; Gjestad R; Løberg EM
    BMC Psychiatry; 2016 Mar; 16():60. PubMed ID: 26973142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical thickness correlates of cognitive performance in cognitively-matched individuals with and without schizophrenia.
    Hanford LC; Pinnock F; Hall GB; Heinrichs RW
    Brain Cogn; 2019 Jun; 132():129-137. PubMed ID: 31005042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal birth weight variation is related to cortical morphology across the psychosis spectrum.
    Haukvik UK; Rimol LM; Roddey JC; Hartberg CB; Lange EH; Vaskinn A; Melle I; Andreassen OA; Dale A; Agartz I
    Schizophr Bull; 2014 Mar; 40(2):410-9. PubMed ID: 23419977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.
    Plitman E; Patel R; Chung JK; Pipitone J; Chavez S; Reyes-Madrigal F; Gómez-Cruz G; León-Ortiz P; Chakravarty MM; de la Fuente-Sandoval C; Graff-Guerrero A
    Neuropsychopharmacology; 2016 Sep; 41(10):2606-13. PubMed ID: 27272768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
    Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
    Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis.
    Fathian F; Løberg EM; Gjestad R; Steen VM; Kroken RA; Jørgensen HA; Johnsen E
    Acta Neuropsychiatr; 2019 Feb; 31(1):36-45. PubMed ID: 30394240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.
    Vincenzi B; Stock S; Borba CP; Cleary SM; Oppenheim CE; Petruzzi LJ; Fan X; Copeland PM; Freudenreich O; Cather C; Henderson DC
    Schizophr Res; 2014 Nov; 159(2-3):395-403. PubMed ID: 25261882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study.
    Liemburg EJ; Nolte IM; ; Klein HC; Knegtering H
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():89-94. PubMed ID: 29778547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.
    Goghari VM; Smith GN; Honer WG; Kopala LC; Thornton AE; Su W; Macewan GW; Lang DJ
    Schizophr Res; 2013 Sep; 149(1-3):149-55. PubMed ID: 23830856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein levels in schizophrenia: a review and meta-analysis.
    Miller BJ; Culpepper N; Rapaport MH
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):223-30. PubMed ID: 23428789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications.
    Fernandes BS; Steiner J; Bernstein HG; Dodd S; Pasco JA; Dean OM; Nardin P; Gonçalves CA; Berk M
    Mol Psychiatry; 2016 Apr; 21(4):554-64. PubMed ID: 26169974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis.
    Ansell BR; Dwyer DB; Wood SJ; Bora E; Brewer WJ; Proffitt TM; Velakoulis D; McGorry PD; Pantelis C
    Psychol Med; 2015 Feb; 45(3):515-27. PubMed ID: 25077698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.